|View printer-friendly version|
|Stereotaxis Announces Next Generation Robotic Magnetic Navigation System and Imaging System|
“I am excited and pleased to introduce Stereotaxis Genesis, the future of robotic electrophysiology,” said David Fischel, Chairman and CEO of Stereotaxis. “Genesis is a new beginning for Stereotaxis. It is the tangible reflection of Stereotaxis’ commitment to innovation that improves patient care, enhances the physician experience, and enables broad availability of robotic electrophysiology.”
The Stereotaxis Genesis RMN system provides the established benefits and reliability of robotic magnetic navigation in a highly innovative architecture that is faster, smaller, lighter and more flexible. Since the original launch of the Niobe® I system in 2003, improvements in Stereotaxis’ robotic system have remained iterative. Genesis RMN utilizes novel smaller magnets that rotate along their center of mass and are held by flexible robotic arms. This mechanism allows for instantaneous responsiveness to physician control and the flexibility to accommodate an increased range of motion. The Genesis RMN system’s significant reduction in size will improve the patient experience and provides physicians and nurses greater access to the patient during the procedure. The system represents a platform able to accommodate significant innovation in the future.
Stereotaxis Genesis RMN is being launched concurrently with Stereotaxis Imaging Model S as an integrated complete solution for a robotic interventional operating room. Stereotaxis Imaging Model S is a single-plane full-power x-ray system designed to be specifically available with the Genesis RMN system. It includes the c-arm, powered table, motorized boom, and large high-definition monitors. Developed in collaboration with Omega Medical Imaging, Stereotaxis Imaging incorporates modern fluoroscopy technology designed to support high quality imaging while minimizing radiation exposure for patients and physicians. The combination of Genesis RMN with Stereotaxis Imaging in a tightly integrated fashion significantly reduces the cost of acquisition, the ongoing cost of ownership, and the complexity of installation of a robotic electrophysiology practice.
“Dr. Natale and I had the opportunity to observe the Genesis and Stereotaxis Imaging systems in person,” said Dr. J. David Burkhardt, cardiac electrophysiologist,
“We are enthusiastic about the reinvigorated robotic innovation by Stereotaxis and are excited to see how this technology advances the field of electrophysiology,” added Dr. Andrea Natale, cardiac electrophysiologist and Executive Medical Director,
“It is very exciting and gratifying that we can improve clinical performance, as well as improve physician and patient experiences, while reducing cost. I want to thank the many Stereotaxis team members and external suppliers that made Genesis a reality. We are delighted to collaborate with Omega Medical Imaging and I want to thank them for making the vision of a complete robotic electrophysiology lab a reality,” said David Fischel, Chairman and CEO of Stereotaxis.
“Omega Medical Imaging prides itself on a long-standing commitment to providing the most reliable and technically advanced interventional imaging systems that put patient and staff safety at the forefront. We are excited to partner with Stereotaxis to advance the future of electrophysiology,” said Brian Fleming, President and CEO of Omega Medical Imaging.
Photos accompanying this announcement are available at:
About Omega Medical Imaging
This press release includes statements that may constitute "forward-looking" statements by Stereotaxis (the Company), usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the